Home › Funds › BOWEN HANES & CO INC › VRTX

BOWEN HANES & CO INC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

BOWEN HANES & CO INC reported holding 153,179 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$80.1M, representing 1.81% of its reported portfolio and ranking #22 among its reported holdings. BOWEN HANES & CO INC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)153.18K sh
Reported value held$80.08M
Portfolio Weight1.81%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BOWEN HANES & CO INC's VRTX position evolved

BOWEN HANES & CO INC first disclosed a stake in VRTX in Q3 2023 at 175,400 shares (US$61.0M). The position peaked in Q1 2025 at 178,909 shares, worth US$86.7M. Across 13 filings, BOWEN HANES & CO INC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 153,179 shares valued at US$80.1M — an increase of 17,780 shares quarter over quarter.. Notable position changes include a 31% trim in Q3 2025 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 175.40K $60.99M New
Q4 2023 173.80K $70.72M Reduce
Q1 2024 177.77K $74.31M Add
Q2 2024 179.50K $84.14M Add
Q3 2024 178.88K $83.20M Hold
Q4 2024 180.62K $72.74M Add
Q1 2025 178.91K $86.74M Reduce
Q2 2025 180.80K $80.49M Add
Q3 2025 124.43K $48.73M Reduce
Q4 2025 133.50K $60.52M Add
Q1 2026 135.40K $60.46M Add
Q2 2026 135.40K $60.46M Hold
Q3 2026 153.18K $80.08M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has BOWEN HANES & CO INC held VRTX?

BOWEN HANES & CO INC has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BOWEN HANES & CO INC's current position in VRTX?

As of Q3 2026, BOWEN HANES & CO INC holds 153.18K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $80.08M, representing 1.81% of its reported portfolio and ranking #22.

Has BOWEN HANES & CO INC been buying or selling VRTX?

In the latest 13F filing (Q3 2026), BOWEN HANES & CO INC increased its position in VRTX. The position peaked in Q1 2025 at 178.91K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.